Novel topiroxostat crystal form and method for preparing same

The invention belongs to the field of chemical pharmaceutical technologies, and particularly relates to a novel topiroxostat crystal form. 2-theta characteristic peaks in X-ray powder diffraction patterns of the novel topiroxostat crystal form are positioned at 5.38+/-0.2, 8.29+/-0.2, 10.78+/-0.2, 15.46+/-0.2, 21.59+/-0.2 and 26.88+/-0.2 degrees. The invention further provides a method for preparing the novel topiroxostat crystal form. The method includes adding topiroxostat into organic solvents; adding alkali into the organic solvents; stirring the topiroxostat and the alkali in the organic solvents until that solid clearly dissolves; adding activated carbon for color removal; filtering the organic solvents to obtain filter liquid; dripping acid in the filter liquid to adjust pH (potential of hydrogen) of the filter liquid until the pH of the filter liquid reaches 6-7; dissolving solid out of the filter liquid; performing extraction filtration on the filter liquid to obtain filter cakes; leaching the filter cakes; drying the filter cakes to obtain the novel topiroxostat crystal form. The novel topiroxostat crystal form and the method have the advantages that the novel topiroxostat crystal form is good in thermal stability and high in wet stability and solubility; products are high in purity, are quite suitable for long-term storage and are suitable for preparing solid preparations with good dissolution and/or stability; the products prepared by the aid of the method have the single and stable crystal form and are quite suitable for industrial production.